Upadacitinib + Vedolizumab: CGH | June 2026

• This multicenter randomized trial evaluated whether combining upadacitinib with vedolizumab during induction therapy could improve outcomes in moderate-to-severe ulcerative colitis.
• A total of 113 patients were randomized to receive either vedolizumab alone or vedolizumab plus upadacitinib for 8 weeks.
• The rationale was to combine the rapid anti-inflammatory effect of a JAK inhibitor with the gut-selective mechanism and favorable long-term safety profile of vedolizumab.
• The combination therapy significantly improved endoscopic remission rates.
• At week 8, endoscopic remission was achieved in 37.5% of patients receiving combination therapy compared with 15.1% receiving vedolizumab alone.
• Clinical remission was also substantially higher with combination treatment (65% vs 35.6%).
• Histologic-endoscopic mucosal improvement, an increasingly important treatment target, was significantly more frequent in the combination arm.
• These findings suggest that early dual-target therapy may help overcome the therapeutic ceiling traditionally observed with advanced monotherapy.
• Importantly, short-term safety appeared reassuring.
• Adverse events were uncommon and occurred at similar rates in both treatment groups.
• No serious adverse events were reported during the 8-week induction period.
• One patient discontinued combination therapy because of severe rash and elevated lipid levels.
• The study supports the emerging concept of a “hit hard and heal early” approach in ulcerative colitis, aiming to achieve deep remission rapidly before transitioning to maintenance therapy.
• Several limitations should be considered:

Open-label design

Early trial termination after interim benefit analysis

Smaller sample size than originally planned

No upadacitinib monotherapy arm

• Ongoing 54-week follow-up will determine whether these impressive induction results translate into durable long-term remission and acceptable long-term safety.

Bottom line: Short-term combination therapy with upadacitinib plus vedolizumab more than doubled endoscopic remission rates compared with vedolizumab alone in moderate-to-severe ulcerative colitis, suggesting a promising new induction strategy that now requires long-term validation.